Vienna, Austria: – Scientists from recombinant proteins specialist CDMO enGenes Biotech GmbH (enGenes) have collaborated with researchers from Germany and the UK in a study that focuses on scalable production of the carbohydrate-recognizing toxins exploited for their significant role in the etiology of many human diseases.
Their research review paper ‘Microbial carbohydrate-binding toxins – From etiology to biotechnological application’ is due for publication in the October 2022 issue of the journal Biotechnology Advances [1] and has just been made available online.
Efficient expression
The study seeks to promote a greater understanding of how to efficiently express and purify recombinant toxins and their carbohydrate-binding domains to enable opportunities for the formulation of innovative biopharmaceuticals that can improve human health.
Lead author Natalia Danielewicz, a doctoral candidate at enGenes and a fellow of the Department of Biotechnology at Vienna’s University of Natural Resources and Life Sciences, and enGenes CEO Dr. Jürgen Mairhofer collaborated on the study with fellow researchers Francesca Rosato and Winfried Römer from the Faculty of Biology and the Signaling Research Centers BIOSS and CIBSS at Albert Ludwigs University, Freiburg, Wenyue Dai from the Freiburg Institute for Advanced Studies (FRIAS), at the University of Freiburg, and Dr W. Bruce Turnbull, of the School of Chemistry and Astbury Centre for Structural Molecular Biology, at University of Leeds, UK.
The study was funded by synBIOcarb European Training Network, which has received funding from the European Union’s Horizon 2020 research and innovation program.
For more information follow: https://www.pharmaceutical-networking.com/engenes-participates-in-the-study-of-large-scale-production-strategies-for-microbial-carbohydrate-binding-toxins/
Comments